Does the media refer more to SRRK or SNDX?

In the previous week, Scholar Rock had 6 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 9 mentions for Scholar Rock and 3 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.02 beat Scholar Rock's score of 0.44 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Syndax Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SNDX or COGT?

In the previous week, Cogent Biosciences had 16 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 19 mentions for Cogent Biosciences and 3 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.02 beat Cogent Biosciences' score of 0.69 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SNDX or MIRM?

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 3 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.02 beat Mirum Pharmaceuticals' score of 0.89 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SNDX or TVTX?

In the previous week, Travere Therapeutics had 8 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 11 mentions for Travere Therapeutics and 3 mentions for Syndax Pharmaceuticals. Travere Therapeutics' average media sentiment score of 1.18 beat Syndax Pharmaceuticals' score of 1.02 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ERAS or SNDX?

In the previous week, Erasca had 1 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 4 mentions for Erasca and 3 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.02 beat Erasca's score of 0.50 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Syndax Pharmaceuticals (SNDX) Competitors

$19.65 -0.10 (-0.51%)

As of 08/21/2026 04:00 PM Eastern

Compare

SNDX vs. SRRK, COGT, MIRM, TVTX, and ERAS

Should you buy Syndax Pharmaceuticals stock or one of its competitors? Syndax Pharmaceuticals's main competitors and comparable companies include Scholar Rock (SRRK), Cogent Biosciences (COGT), Mirum Pharmaceuticals (MIRM), Travere Therapeutics (TVTX), and Erasca (ERAS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Syndax Pharmaceuticals compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

In the previous week, Scholar Rock had 6 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 9 mentions for Scholar Rock and 3 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.02 beat Scholar Rock's score of 0.44 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syndax Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

91.1% of Scholar Rock shares are held by institutional investors. 10.3% of Scholar Rock shares are held by insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Scholar Rock presently has a consensus target price of $58.77, suggesting a potential upside of 4.02%. Syndax Pharmaceuticals has a consensus target price of $41.55, suggesting a potential upside of 111.43%. Given Syndax Pharmaceuticals' higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	3.13
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Scholar Rock has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Scholar Rock's return on equity of -160.19% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%

Syndax Pharmaceuticals has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Syndax Pharmaceuticals	$172.35M	10.10	-$285.42M	-$2.51	N/A

Summary

Scholar Rock and Syndax Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Cogent Biosciences?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Syndax Pharmaceuticals has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	10.10	-$285.42M	-$2.51	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

Syndax Pharmaceuticals presently has a consensus target price of $41.55, suggesting a potential upside of 111.43%. Cogent Biosciences has a consensus target price of $49.40, suggesting a potential upside of 34.49%. Given Syndax Pharmaceuticals' higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

In the previous week, Cogent Biosciences had 16 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 19 mentions for Cogent Biosciences and 3 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.02 beat Cogent Biosciences' score of 0.69 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Syndax Pharmaceuticals has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Cogent Biosciences has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Cogent Biosciences' return on equity of -84.47% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Cogent Biosciences	N/A	-84.47%	-47.72%

Summary

Syndax Pharmaceuticals beats Cogent Biosciences on 8 of the 13 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Syndax Pharmaceuticals has a net margin of -87.52% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Mirum Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	10.10	-$285.42M	-$2.51	N/A
Mirum Pharmaceuticals	$521.31M	12.00	-$23.36M	-$14.55	N/A

Syndax Pharmaceuticals presently has a consensus price target of $41.55, suggesting a potential upside of 111.43%. Mirum Pharmaceuticals has a consensus price target of $137.33, suggesting a potential upside of 42.60%. Given Syndax Pharmaceuticals' higher probable upside, research analysts plainly believe Syndax Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 3 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.02 beat Mirum Pharmaceuticals' score of 0.89 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Syndax Pharmaceuticals has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

Summary

Mirum Pharmaceuticals beats Syndax Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Travere Therapeutics?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Travere Therapeutics has a net margin of -7.35% compared to Syndax Pharmaceuticals' net margin of -87.52%. Travere Therapeutics' return on equity of -55.15% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

Travere Therapeutics has higher revenue and earnings than Syndax Pharmaceuticals. Travere Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	10.10	-$285.42M	-$2.51	N/A
Travere Therapeutics	$490.73M	12.62	-$25.55M	-$0.46	N/A

Syndax Pharmaceuticals has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

In the previous week, Travere Therapeutics had 8 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 11 mentions for Travere Therapeutics and 3 mentions for Syndax Pharmaceuticals. Travere Therapeutics' average media sentiment score of 1.18 beat Syndax Pharmaceuticals' score of 1.02 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Syndax Pharmaceuticals currently has a consensus target price of $41.55, suggesting a potential upside of 111.43%. Travere Therapeutics has a consensus target price of $61.67, suggesting a potential downside of 6.15%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Travere Therapeutics beats Syndax Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Erasca?

Erasca (NASDAQ:ERAS) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

67.8% of Erasca shares are owned by institutional investors. 14.2% of Erasca shares are owned by insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Erasca has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Erasca's return on equity of -38.43% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-38.43%	-32.05%
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%

Erasca has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

Erasca currently has a consensus price target of $22.09, indicating a potential upside of 25.30%. Syndax Pharmaceuticals has a consensus price target of $41.55, indicating a potential upside of 111.43%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Erasca has higher earnings, but lower revenue than Syndax Pharmaceuticals. Erasca is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A
Syndax Pharmaceuticals	$172.35M	10.10	-$285.42M	-$2.51	N/A

In the previous week, Erasca had 1 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 4 mentions for Erasca and 3 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.02 beat Erasca's score of 0.50 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syndax Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Erasca beats Syndax Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Syndax Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNDX vs. The Competition

Export

Metric	Syndax Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.74B	$4.01B	$7.37B	$12.83B
Dividend Yield	N/A	3.64%	2.53%	10.78%
P/E Ratio	-7.83	11.62	272.33	24.21
Price / Sales	10.10	1,342.82	625.09	94.86
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	26.55	17.38	11.25	6.42
Net Income	-$285.42M	-$22.72M	$3.47B	$348.89M
7 Day Performance	-0.96%	3.29%	2.09%	0.08%
1 Month Performance	-7.36%	8.23%	6.64%	3.88%
1 Year Performance	21.00%	55.05%	25.02%	16.98%

Syndax Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNDX Syndax Pharmaceuticals	2.7415 of 5 stars	$19.65 -0.5%	$41.55 +111.4%	+21.0%	$1.74B	$172.35M	N/A	110	Positive News Analyst Forecast
SRRK Scholar Rock	1.6469 of 5 stars	$56.50 +2.3%	$57.71 +2.1%	+59.2%	$6.88B	N/A	N/A	140	News Coverage Analyst Forecast
COGT Cogent Biosciences	2.4857 of 5 stars	$36.73 +4.0%	$49.40 +34.5%	+203.1%	$6.37B	N/A	N/A	80	Trending News Analyst Upgrade Analyst Revision
MIRM Mirum Pharmaceuticals	3.5504 of 5 stars	$96.31 -0.8%	$137.33 +42.6%	+34.7%	$6.25B	$618.07M	N/A	140	Insider Trade
TVTX Travere Therapeutics	1.9226 of 5 stars	$65.71 +1.9%	$61.67 -6.2%	+266.7%	$6.19B	$591.33M	N/A	460	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNDX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Syndax Pharmaceuticals (SNDX) Competitors

SNDX vs. SRRK, COGT, MIRM, TVTX, and ERAS

How does Syndax Pharmaceuticals compare to Scholar Rock?

Summary

How does Syndax Pharmaceuticals compare to Cogent Biosciences?

Summary

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does Syndax Pharmaceuticals compare to Travere Therapeutics?

Summary

How does Syndax Pharmaceuticals compare to Erasca?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX vs. The Competition

Syndax Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Syndax Pharmaceuticals (SNDX) Competitors

SNDX vs. SRRK, COGT, MIRM, TVTX, and ERAS

How does Syndax Pharmaceuticals compare to Scholar Rock?

Does the media refer more to SRRK or SNDX?

Which has more volatility & risk, SRRK or SNDX?

Do insiders & institutionals have more ownership in SRRK or SNDX?

Do analysts recommend SRRK or SNDX?

Is SRRK or SNDX more profitable?

Which has preferable valuation & earnings, SRRK or SNDX?

Summary

How does Syndax Pharmaceuticals compare to Cogent Biosciences?

Which has better earnings & valuation, SNDX or COGT?

Do analysts rate SNDX or COGT?

Does the media refer more to SNDX or COGT?

Which has more volatility and risk, SNDX or COGT?

Is SNDX or COGT more profitable?

Summary

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Is SNDX or MIRM more profitable?

Which has stronger valuation & earnings, SNDX or MIRM?

Do analysts rate SNDX or MIRM?

Does the media refer more to SNDX or MIRM?

Which has more volatility & risk, SNDX or MIRM?

Summary

How does Syndax Pharmaceuticals compare to Travere Therapeutics?

Is SNDX or TVTX more profitable?

Which has better earnings and valuation, SNDX or TVTX?

Which has more volatility and risk, SNDX or TVTX?

Does the media prefer SNDX or TVTX?

Do analysts recommend SNDX or TVTX?

Summary

How does Syndax Pharmaceuticals compare to Erasca?

Do institutionals & insiders have more ownership in ERAS or SNDX?

Is ERAS or SNDX more profitable?

Which has more risk & volatility, ERAS or SNDX?

Do analysts recommend ERAS or SNDX?

Which has better earnings and valuation, ERAS or SNDX?

Does the media refer more to ERAS or SNDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX vs. The Competition

Syndax Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools